Stereotaxis Announces Uplisting to NYSE American
September 03 2019 - 4:05PM
Stereotaxis (OTCQX: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, today
announced that its common stock has been approved for listing on
the NYSE American. The Company’s common stock will begin trading on
the NYSE American exchange under its current symbol, “STXS,” at the
open of trading on Sept. 6, 2019. The Company’s common stock will
continue to trade on the OTCQX until the close of the market on
Sept. 5, 2019.
David Fischel, Chairman and CEO of Stereotaxis,
commented, “We are excited to list on the NYSE American. This is
another milestone in our effort to improve awareness of our
differentiated technology, clinical value, and growth opportunity.
Listing on the NYSE American should support a more robust capital
market for existing and new shareholders.”
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. Stereotaxis’ robotic technology has
received various regulatory clearances in the United States,
European Union, Japan, Canada, China, and elsewhere. The
Stereotaxis Genesis RMN System is CE marked and will become
available in other global geographies subject to regulatory
approvals. Stereotaxis Imaging Model S is CE marked and FDA
cleared. For more information, please visit
www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the Company's ability to raise additional capital on a
timely basis and on terms that are acceptable, its ability to
continue to manage expenses and cash burn rate at sustainable
levels, its ability to continue to work with lenders to extend,
repay or refinance indebtedness, or to obtain additional financing,
in either case on acceptable terms, continued acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from healthcare reform in the United
States, including changes in government reimbursement procedures,
dependence upon third-party vendors, timing of regulatory
approvals, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments in any particular period or at all because some
of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified,
delayed or canceled, either by their express terms, as a result of
negotiations, or by overall project changes or delays.
Company Contacts: David L. FischelChairman
and Chief Executive Officer
Martin C. StammerChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2023 to Apr 2024